Table 1.

Clinical Trials for JAK-STAT/TNF Pathway modifiers in HNSCC or GC.

Inhibitor/ Modulator	Inhibitor Agent/Adjuvant Therapy	Phase	Clinical Trial	Status (11 Nov. 2021)	Ref/results
STAT3	BBI-608(Napaucasin)/paclitaxel	Ib/II	NCT01325441	Completed a	223
		III	NCT02178956	Completed h	224
STAT3	OPB-111077 - SH2 domain binder	I	NCT01711034	Completed a	225
STAT3	TTI-101/C188-9 – SH2 domain binder	I	NCT03195699	Recruiting b	None
STAT3	AZD9150 (ISIS 481464) – antisense oligo	I/II	NCT01563302	Completed c	226
STAT3	OPB-31121 - SH2 domain binder	I	NCT00955812	Completed d	227
		I	NCT00657176	Unknown d	228
STAT3	OPB-51602 - SH2 domain binder	I	NCT02058017	Terminated e	None
		I	NCT01423903	Completed a	None
		I	NCT01184807	Completed d	None
		I	NCT01867073	Active, not recruiting d	None
STAT3	STAT3 decoy - Oligonucleotide	0	NCT00696176	Completed f	229
STAT3	AZD9150/ anti-PD-L1 (Durvalumab)	Ib/II	NCT02499328	Active, not recruiting f	Submitted-not posted
STAT3	IMX-10 (curcumin/doxorubicin)	I/II	NCT03382340	Recruiting d	None
STAT3	PROTAC (KT-333)	I	NCT05225584	Recruiting c	230
JAK1	Itacitinib (INC039110)/pembrolizumab, anti-PD-1)	Ib	NCT02646748	Active, not recruiting d	None
JAK1/2	AZD-1480	I	NCT01112397	Terminated d	231
		I	NCT01219543	Terminated g	None
	Ruxolitinib	II	NCT03153982	Recruiting f	None
		0	NCT02593929	Withdrawn f	None
IL-6Ra	Tocilizumab (anti-IL-6Ra) / atezolizumab (anti-PD-L1)	II	NCT03708224	Recruiting f	None
	Siltuximab	I/II	NCT00841191	Completed d	232
IRX-2 biologic (Il-1β, Il-2, IL-6, IFNγ, TNF, GMCSF)	IRX-2/ cyclophosphamide, pembrolizumab	I/II	NCT03918499	temporary on hold h	None
	IRX-2/ cyclophosphamide, indomethacin, omeprazole, zinc	II	NCT02609386	Active not recruiting i	None
	IRX-2/ anti-PD-L1 (Durvalumab)	I	NCT03381183	Active not recruiting f	None
	IRX-2/Nivolumab	I	NCT03758781	Active not recruiting j	233
	IRX-2/cyclophosphamide, indomethacin, omeprazole, zinc	II	NCT00210470	Completed f	234
EGFR	Cetuximab/cisplatin/docetaxel/radiation	II	NCT00084318	Completed f	235
	Cetuximab/cisplatin/bortezomib/radiation	I	NCT01445405	Completed f	None
	Cetuximab/pembrolizumab (anti-PD-1)/radiation	II	NCT02707588	Active not recruiting f	236
cIAP1/2	Smac-mimetic (Debio1143)/cisplatin/radiation	I/II	NCT02022098	Active, not recruiting f	237
cIAP1/2	Smac-mimetiAc (Debio1143)/ Cisplatin/IMRT	III	NCT04459715	Recruiting f	None

^aAdvanced malignancies.

^bHNSCC, gastric adenocarcinoma, plus other solid tumor types.

^cAdvanced cancers or hematological malignancies.

^dAdvanced cancers and/or solid tumors.

^eLocally advanced nasopharyngeal carcinoma

^fHNSCC.

^gAdvanced solid malignancies, with GC in the expansion phase.

^hgastric or gastroesophageal junction cancer.

ⁱSquamous carcinoma of the oral cavity. IMRT (Intensity Modulation Radiation Therapy).

^jrecurrent/metastatic solid tumors including HNSCC.